CA2557719A1 - 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy - Google Patents
4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy Download PDFInfo
- Publication number
- CA2557719A1 CA2557719A1 CA002557719A CA2557719A CA2557719A1 CA 2557719 A1 CA2557719 A1 CA 2557719A1 CA 002557719 A CA002557719 A CA 002557719A CA 2557719 A CA2557719 A CA 2557719A CA 2557719 A1 CA2557719 A1 CA 2557719A1
- Authority
- CA
- Canada
- Prior art keywords
- formula
- compounds
- methyl
- compound
- ylmethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/38—One sulfur atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Neurology (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04100830 | 2004-03-02 | ||
| EP04100830.1 | 2004-03-02 | ||
| PCT/EP2005/001814 WO2005094828A1 (en) | 2004-03-02 | 2005-02-22 | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2557719A1 true CA2557719A1 (en) | 2005-10-13 |
Family
ID=34896109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002557719A Abandoned CA2557719A1 (en) | 2004-03-02 | 2005-02-22 | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as gaba receptor ligands for the treatment of anxiety, depression and epilepsy |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7351700B2 (https=) |
| EP (1) | EP1725239B1 (https=) |
| JP (1) | JP4563447B2 (https=) |
| KR (1) | KR100802863B1 (https=) |
| CN (1) | CN1925859B (https=) |
| AT (1) | ATE367163T1 (https=) |
| AU (1) | AU2005229505B2 (https=) |
| BR (1) | BRPI0508310A (https=) |
| CA (1) | CA2557719A1 (https=) |
| DE (1) | DE602005001696T2 (https=) |
| ES (1) | ES2290885T3 (https=) |
| PL (1) | PL1725239T3 (https=) |
| RU (1) | RU2382033C2 (https=) |
| WO (1) | WO2005094828A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2353619C2 (ru) | 2007-06-28 | 2009-04-27 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции |
| RU2354647C2 (ru) * | 2007-06-28 | 2009-05-10 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе |
| CA2692945A1 (en) * | 2007-07-09 | 2009-01-15 | Astrazeneca Ab | Compounds - 945 |
| TW201623257A (zh) | 2014-05-09 | 2016-07-01 | 奧利安公司 | 藥理活性之喹唑啉二酮衍生物 |
| KR102269132B1 (ko) | 2014-06-10 | 2021-06-25 | 삼성디스플레이 주식회사 | 반방향족성 화합물 및 이를 포함하는 유기 발광 소자 |
| US10084141B2 (en) | 2014-06-13 | 2018-09-25 | Samsung Display Co., Ltd. | Antiaromatic compound and organic light-emitting device including the same |
| HU231058B1 (hu) | 2017-03-13 | 2020-04-28 | Richter Gedeon Nyrt. | Gyógyászatilag hatékony aliciklusos-szubsztituált pirazolo[1,5-a]pirimidin származékok |
| TWI907472B (zh) | 2020-08-05 | 2025-12-11 | 匈牙利商羅特格登公司 | 具藥理活性之經雜環取代的吡唑并〔１，５－ａ〕嘧啶衍生物 |
| GB202414197D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414199D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel Compounds |
| GB202414200D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414193D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
| GB202414192D0 (en) | 2024-09-27 | 2024-11-13 | Addex Pharmaceuticals Sa | Novel compounds |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6313146B1 (en) | 1991-08-23 | 2001-11-06 | Nps Pharmaceuticals, Inc. | Calcium receptor-active molecules |
| RU2153494C2 (ru) * | 1993-10-12 | 2000-07-27 | Дзе Дюпон Мерк Фармасьютикал Компани | 1-n-алкил-n-арилпиримидинамины, способ лечения заболеваний, фармацевтическая композиция |
| WO2001056990A2 (en) | 2000-02-03 | 2001-08-09 | Eli Lilly And Company | Pyridine derivates as potentiators of glutamate receptors |
| CA2444148A1 (en) * | 2001-04-11 | 2002-10-24 | Queen's University At Kingston | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents |
| GB0209481D0 (en) | 2002-04-24 | 2002-06-05 | Novartis Ag | Organic compounds |
-
2005
- 2005-02-22 KR KR1020067017683A patent/KR100802863B1/ko not_active Expired - Fee Related
- 2005-02-22 AT AT05707562T patent/ATE367163T1/de active
- 2005-02-22 AU AU2005229505A patent/AU2005229505B2/en not_active Ceased
- 2005-02-22 CN CN2005800066192A patent/CN1925859B/zh not_active Expired - Fee Related
- 2005-02-22 CA CA002557719A patent/CA2557719A1/en not_active Abandoned
- 2005-02-22 JP JP2007501167A patent/JP4563447B2/ja not_active Expired - Fee Related
- 2005-02-22 WO PCT/EP2005/001814 patent/WO2005094828A1/en not_active Ceased
- 2005-02-22 DE DE602005001696T patent/DE602005001696T2/de not_active Expired - Lifetime
- 2005-02-22 BR BRPI0508310-9A patent/BRPI0508310A/pt not_active IP Right Cessation
- 2005-02-22 PL PL05707562T patent/PL1725239T3/pl unknown
- 2005-02-22 EP EP05707562A patent/EP1725239B1/en not_active Expired - Lifetime
- 2005-02-22 ES ES05707562T patent/ES2290885T3/es not_active Expired - Lifetime
- 2005-02-22 RU RU2006134632/04A patent/RU2382033C2/ru not_active IP Right Cessation
- 2005-02-23 US US11/064,046 patent/US7351700B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| KR100802863B1 (ko) | 2008-02-12 |
| WO2005094828A1 (en) | 2005-10-13 |
| KR20060116240A (ko) | 2006-11-14 |
| EP1725239B1 (en) | 2007-07-18 |
| RU2006134632A (ru) | 2008-04-10 |
| EP1725239A1 (en) | 2006-11-29 |
| DE602005001696D1 (de) | 2007-08-30 |
| US20050197337A1 (en) | 2005-09-08 |
| CN1925859B (zh) | 2010-11-24 |
| AU2005229505A1 (en) | 2005-10-13 |
| AU2005229505B2 (en) | 2010-07-15 |
| BRPI0508310A (pt) | 2007-07-24 |
| DE602005001696T2 (de) | 2008-04-10 |
| JP4563447B2 (ja) | 2010-10-13 |
| PL1725239T3 (pl) | 2007-12-31 |
| ES2290885T3 (es) | 2008-02-16 |
| US7351700B2 (en) | 2008-04-01 |
| JP2007526266A (ja) | 2007-09-13 |
| CN1925859A (zh) | 2007-03-07 |
| RU2382033C2 (ru) | 2010-02-20 |
| ATE367163T1 (de) | 2007-08-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1828199B1 (en) | Thieno-pyridine derivatives as gaba-b allosteric enhancers | |
| AU2005229505B2 (en) | 4- (sulfanyl-pyrimidin-4-ylmethyl) -morpholine derivatives and related compounds as GABA receptor ligands for the treatment of anxiety, depression and epilepsy | |
| WO2017026516A1 (ja) | イソチアゾール誘導体 | |
| SK143394A3 (en) | 7-(2-aminoethyl)benzothiazolones, method of their production and pharmaceutical agents, which contains thereof as effective matters | |
| JPWO2016148232A1 (ja) | モルヒナン誘導体 | |
| KR20230170933A (ko) | TRPA1 억제제로서 3H,4H,5H,6H,7H-피리미도[4,5-b][1,4]옥사진-4,6-디온 유도체 | |
| TW202229292A (zh) | 作為trpa1抑制劑之四唑衍生物 | |
| CN117083269A (zh) | 作为trpa1抑制剂的尿嘧啶衍生物 | |
| US5432192A (en) | Tricyclic compounds and method for treating allergic diseases | |
| CN117222652A (zh) | 作为TRPA1抑制剂的3H,4H‐噻吩并[2,3-d]嘧啶-4-酮衍生物 | |
| TW202229293A (zh) | 作為trpa1抑制劑之四唑衍生物 | |
| TW200904449A (en) | Dibenzo[b,f][1,4]oxazapine compounds | |
| US6562810B1 (en) | 8-substituted-9H-1,3-dioxolo/4,5-h//2,3/benzodiazepine derivatives, as AMPA/kainate receptor inhibitors | |
| EP1915357B1 (en) | 2-hydroxy-propionic acid derivatives and 3-hydroxy-benzofuran-2-one derivatives with affinity for the gaba-b-receptor | |
| TW202216688A (zh) | 作為trpa1抑制劑之四唑衍生物 | |
| CN121270577A (zh) | 作为trpa1抑制剂的四唑衍生物 | |
| MXPA06009949A (es) | Derivados 4-(sulfanil-pirimidin-4-ilmetil)-morfolina y compuestos relacionados como ligandos del receptor gaba para el tratamiento contra ansiedad, depresion y epilepsia | |
| CN101597260A (zh) | 新的毒蕈碱受体拮抗剂及其用途 | |
| US7348332B2 (en) | (3,4-dihydro-quinazolin-2-yl)-indan-1-yl-amines | |
| JPH05331065A (ja) | セロトニン神経系関連疾患治療剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| FZDE | Discontinued |
Effective date: 20130222 |